Next Article in Journal
Novel Sulfamethoxazole Ureas and Oxalamide as Potential Antimycobacterial Agents
Next Article in Special Issue
ABC Transport Proteins in Cardiovascular Disease—A Brief Summary
Previous Article in Journal
Choerosponins A and B, Two New Cytotoxic Bridged-Ring Ketones and the Determination of Their Absolute Configurations
Previous Article in Special Issue
New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Molecules 2017, 22(4), 539; doi:10.3390/molecules22040539

Harnessing Solute Carrier Transporters for Precision Oncology

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Department of Pharmaceutics, University of Washington, Seattle, WA 98195, USA
Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98195 USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Author to whom correspondence should be addressed.
Academic Editor: Maria Emília de Sousa
Received: 27 February 2017 / Revised: 21 March 2017 / Accepted: 22 March 2017 / Published: 28 March 2017
(This article belongs to the Special Issue Can Membrane Transporters Contribute to Drug Discovery?)
View Full-Text   |   Download PDF [272 KB, uploaded 4 April 2017]


Solute Carrier (SLC) transporters are a large superfamily of transmembrane carriers involved in the regulated transport of metabolites, nutrients, ions and drugs across cellular membranes. A subset of these solute carriers play a significant role in the cellular uptake of many cancer therapeutics, ranging from chemotherapeutics such as antimetabolites, topoisomerase inhibitors, platinum-based drugs and taxanes to targeted therapies such as tyrosine kinase inhibitors. SLC transporters are co-expressed in groups and patterns across normal tissues, suggesting they may comprise a coordinated regulatory circuit serving to mediate normal tissue functions. In cancer however, there are dramatic changes in expression patterns of SLC transporters. This frequently serves to feed the increased metabolic demands of the tumor cell for amino acids, nucleotides and other metabolites, but also presents a therapeutic opportunity, as increased transporter expression may serve to increase intracellular concentrations of substrate drugs. In this review, we examine the regulation of drug transporters in cancer and how this impacts therapy response, and discuss novel approaches to targeting therapies to specific cancers via tumor-specific aberrations in transporter expression. We propose that among the oncogenic changes in SLC transporter expression there exist emergent vulnerabilities that can be exploited therapeutically, extending the application of precision medicine from tumor-specific drug targets to tumor-specific determinants of drug uptake. View Full-Text
Keywords: solute carrier transporters; drug transport; chemotherapy; precision medicine; targeted therapy; SLC35F2; Survivin; YM155; precision oncology solute carrier transporters; drug transport; chemotherapy; precision medicine; targeted therapy; SLC35F2; Survivin; YM155; precision oncology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nyquist, M.D.; Prasad, B.; Mostaghel, E.A. Harnessing Solute Carrier Transporters for Precision Oncology. Molecules 2017, 22, 539.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top